Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2015 (2015), Article ID 938264, 3 pages
http://dx.doi.org/10.1155/2015/938264
Case Report

Postinjection Muscle Fibrosis from Lupron

1Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
2Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA

Received 14 March 2015; Accepted 13 May 2015

Academic Editor: Giovanni Montini

Copyright © 2015 Erica Everest et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We describe the case of a 6.5-year-old girl with central precocious puberty (CPP), which signifies the onset of secondary sexual characteristics before the age of eight in females and the age of nine in males as a result of stimulation of the hypothalamic-pituitary-gonadal axis. Her case is likely related to her adoption, as children who are adopted internationally have much higher rates of CPP. She had left breast development at Tanner Stage 2, adult body odor, and mildly advanced bone age. In order to halt puberty and maximize adult height, she was prescribed a gonadotropin releasing hormone analog, the first line treatment for CPP. She was administered Lupron (leuprolide acetate) Depot-Ped (3 months) intramuscularly. After her second injection, she developed swelling and muscle pain at the injection site on her right thigh. She also reported an impaired ability to walk. She was diagnosed with muscle fibrosis. This is the first reported case of muscle fibrosis resulting from Lupron injection.